**ELAFIBRANOR: A LIVER TARGETED PPARα/δ AGONIST FOR A GLOBAL MANAGEMENT OF NASH PATIENTS**


**BACKGROUND**

Elafibranor is a new dual PPARα/δ agonist.

- Elafibranor is liver targeted.
- For activating both PPARα and PPARδ in both parenchymal cells (hepatocytes) and non-parenchymal cells (fibroblasts), with minimal pathways of HNF4α up-regulation.

**AIM**

- This poster summarizes key preclinical and Phase II clinical data demonstrating efficacy of elafibranor in animal and human models of NASH.

**ELAFIBRANOR IN DISEASE MODELS OF LIVER FIBROSIS**

**GOLDEN-505: A 1-YEAR PHASE 2B IN NASH**

- Elafibranor-120mg lowered plasma liver markers.
- Elafibranor-120mg improved NASH activity.

**PHASE 2A: ELAFIBRANOR IS AN INSULIN SENSitizer**

- A glucose clamp trial in insulin-resistant patients (GFT505-210-6).
- Elafibranor reversed CarbonTetraChloride CCl4 induced fibrosis and favored the regeneration of the liver.

**REFERENCES**

- EASL NASH Monothematic Conference, Riga, 2016
- EASL NASH Monothematic Conference, Riga, 2016